AS04-HPV-16/18疫苗妊娠期暴露登记研究结果
该研究通过英国和美国的妊娠暴露登记系统,收集2007年9月至2015年11月间181例前瞻性可评估的妊娠暴露报告,评估孕前60天内或孕期接种AS04-HPV-16/18疫苗后的妊娠结局。结果显示85.1%活产,7.7%自然流产,0.5%死胎,6.6%人工终止,未发现先天异常聚集或提示致畸性的模式。
要点
- 181例可评估妊娠中,活产154例(85.1%),自然流产14例(7.7%),死胎1例(0.5%),人工终止12例(6.6%)。
- 18例婴儿先天异常,包括9例轻微结构缺陷、7例重大结构缺陷、1例遗传性疾病、1例可能先天性感染所致。
- 未发现先天异常聚集或提示致畸性的模式。
核心结论
- 登记数据补充了临床试验和上市后监测的其他数据,显示在定义的暴露期(受孕前60天至分娩)接种AS04-HPV-16/18疫苗没有增加致畸性风险的证据。
研究设计与样本
- 在英国和美国建立妊娠暴露登记系统,自愿报告,暴露定义为估计受孕日前60天内至分娩期间接种AS04-HPV-16/18疫苗。
- 2007年9月至2015年11月间收到306例妊娠暴露报告,其中181例为前瞻性可评估报告。
主要发现
- 181例可评估报告中,154例(85.1%)活产,14例(7.7%)自然流产,1例(0.5%)死胎,12例(6.6%)人工终止。
- 结局与暴露时间无聚集现象。
- 18例婴儿先天异常:9例轻微结构缺陷、7例重大结构缺陷、1例遗传性疾病、1例可能为先天性感染所致。
- 3例结构缺陷(2例轻微、1例重大)与妊娠关键发育期接种有时间关联。
- 未发现先天异常聚集或模式提示可能致畸性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess pregnancy outcomes after exposure to AS04-HPV-16/18 vaccine (Cervarix, GSK, Belgium) prior to, or during pregnancy, as reported to a pregnancy registry. METHODS: A pregnancy exposure registry was established to collect data in the United Kingdom and the United States. Exposure was defined as vaccination with AS04-HPV-16/18 within 60days before the estimated conception date and delivery. Reporting was voluntary. RESULTS: Between September 2007 and November 2015, 306 pregnancy exposure reports were received of which 181 were prospective, evaluable reports. From these 181 reports, 154 (85.1%) pregnancies resulted in a live birth, 14 (7.7%) in spontaneous abortion, one (0.5%) in stillbirth, and 12 (6.6%) were electively terminated. There was no clustering of outcomes with respect to the timing of exposure. There were 18 infants born with a congenital anomaly of which nine were minor structural defects, seven were major structural defects, one was a hereditary disorder and one was likely the result of a congenital infection. In three cases of structural defect (two minor and one major), there was a temporal association to vaccination during the critical developmental period of gestation. There was no cluster or constellation of congenital anomalies suggestive of possible teratogenesis. CONCLUSION: The pharmacovigilance plan to investigate the effects of inadvertent exposure to AS04-HPV-16/18 vaccine during pregnancy included assessment of pregnancy outcomes among women enrolled in clinical trials, evaluation of pregnancy exposure reports from all countries as part of routine passive safety surveillance, a large, well conducted post-authorization observational study, and the pregnancy registry. These registry data complement other data from clinical trials and post-marketing surveillance showing no evidence that vaccination with AS04-HPV-16/18 during the defined exposure period (within 60days before conception until delivery) increases the risk of teratogenicity.
引用
- López-Fauqued M, Zima J, Angelo MG, et al. Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine. Vaccine. 2017. PMID: 28863867. doi:10.1016/j.vaccine.2017.08.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。